Autosomal Recessive Hypotrichosis
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Autosomal Recessive Hypotrichosis

What is the definition of Autosomal Recessive Hypotrichosis?

Autosomal recessive hypotrichosis is a condition that affects hair growth. People with this condition have sparse hair (hypotrichosis) on the scalp beginning in infancy. This hair is usually coarse, dry, and tightly curled (often described as woolly hair). Scalp hair may also be lighter in color than expected and is fragile and easily broken. Affected individuals often cannot grow hair longer than a few inches. The eyebrows, eyelashes, and other body hair may be sparse as well. Over time, the hair problems can remain stable or progress to complete scalp hair loss (alopecia) and a decrease in body hair.

What are the causes of Autosomal Recessive Hypotrichosis?

Autosomal recessive hypotrichosis can be caused by mutations in the LIPH, LPAR6, or DSG4 gene. These genes provide instructions for making proteins that are involved in the growth and division (proliferation) and maturation (differentiation) of cells within hair follicles. These cell processes are important for the normal development of hair follicles and for hair growth; as the cells in the hair follicle divide, the hair strand (shaft) is pushed upward and extends beyond the skin, causing the hair to grow. The proteins produced from the LIPH, LPAR6, and DSG4 genes are also found in the outermost layer of skin (the epidermis) and glands in the skin that produce a substance that protects the skin and hair (sebaceous glands).

How prevalent is Autosomal Recessive Hypotrichosis?

The worldwide prevalence of autosomal recessive hypotrichosis is unknown. In Japan, the condition is estimated to affect 1 in 10,000 individuals.

Is Autosomal Recessive Hypotrichosis an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Autosomal Recessive Hypotrichosis Local Doctors?
David Norris
Elite in Autosomal Recessive Hypotrichosis
Dermatology
Elite in Autosomal Recessive Hypotrichosis
Dermatology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
Languages Spoken:
English

David Norris is a Dermatologist in Aurora, Colorado. Dr. Norris is rated as an Elite provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Eosinophilic Fasciitis, and Female Pattern Baldness.

Elite in Autosomal Recessive Hypotrichosis
Elite in Autosomal Recessive Hypotrichosis

UCI Health Newport Beach

2161 San Joaquin Hills Rd, 
Newport Beach, CA 
Languages Spoken:
English
Offers Telehealth

Natasha Mesinkovska is a Dermatologist in Newport Beach, California. Dr. Mesinkovska is rated as an Elite provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Alopecia Universalis, and Vitiligo.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Autosomal Recessive Hypotrichosis
Elite in Autosomal Recessive Hypotrichosis

Dr Jane Asprinio O'Brien PA

1295 NW 14th St, 
Miami, FL 
Languages Spoken:
English
Offers Telehealth

Antonella Tosti is a Dermatologist in Miami, Florida. Dr. Tosti is rated as an Elite provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Splinter Hemorrhages, and Ringworm.

What are the latest Autosomal Recessive Hypotrichosis Clinical Trials?
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study

Summary: Research Purpose The objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA). Study Content This clinical trial is a randomized (1:1), multicenter, parallel-group, controlled study. AGA patients aged 18 to 60 years presenting to the participating centers will be recruited. After providing informed consent, eligible...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata

Summary: The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Who are the sources who wrote this article ?

Published Date: April 01, 2013
Published By: National Institutes of Health